News
"In clinical trials, TIVDAK demonstrated a superior overall survival benefit and manageable safety profile compared to chemotherapy, supporting its position to become a potential new standard of ...
TIVDAK® is the first and only antibody-drug conjugate (ADC) approved to treat recurrent or metastatic cervical cancer with disease progression on or after systemic therapy In the global Phase 3 ...
COPENHAGEN, Denmark--(BUSINESS WIRE)-- Genmab A/S (GMAB) (Nasdaq: GMAB) today announced that the Japan Ministry of Health, Labour and Welfare has approved TIVDAK ® (tisotumab vedotin) for the ...
Genmab has announced that the European Commission (EC) has approved Tivdak (tisotumab vedotin) to treat recurrent or metastatic cervical cancer.
"In clinical trials, TIVDAK demonstrated a superior overall survival benefit and manageable safety profile compared to chemotherapy, supporting its position to become a potential new standard of care ...
Genmab (GMAB) announced that the European Commission has granted marketing authorization for TIVDAK, an antibody-drug conjugate, as monotherapy ...
Genmab A/S(Nasdaq: GMAB) announced today that the European Commission (EC) has granted marketing authorization for TIVDAK ® (tisotumab vedotin), an antibody-drug conjugate (ADC), as monotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results